Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Contact:

NCT Number:

Protocol:

AAAR5314

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

Axitinib (AG-013736) is an investigational (experimental) drug that is being studied in patients with metastatic pheochromocytoma/paraganglioma. The main goal of this study is to find out if axitinib is able to stop tumors from growing, or shrink tumors in patients with this type of cancer.

Are you Eligible? (Inclusion Criteria)

  • Age ≥ 18 years
  • A life expectancy of at least 3 months
  • ECOG performance status ≤ 2

Specialty Area(s)

Principal Investigator

Profile Headshot
  • Co-Director, Adrenal Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032